News

Patents

Plasseraud IP at the BIO-Europe Spring

03 March, 2026

The BIO-Europe Spring conference will take place in Lisbon from March 23 to 25, 2026.
Our experts Marion Puimatto, French & European Patent Attorney, and Ellen Broug, European Patent Attorney, will be present at the BIO-Europe Spring by Informa.

BIO Europe Spring is the leading international event for the life sciences ecosystem biotechnology, pharmaceuticals, healthcare, research, and investment bringing together every year thousands of decision makers, start ups, biotech companies, researchers, investors, and major pharmaceutical groups.

At Plasseraud IP, we support players in the pharmaceutical and biotechnology sectors in both defining and implementing intellectual property and litigation strategies in Europe and internationally.

For more information : BIO-Europe Spring | Europe's Largest Springtime Biotech Partnering Event

On the same expertise
By the same author

On the same expertise

Plasseraud IP is recognized by the Unified Patent Court (UPC) for its expertise in mediation and patent expertise !

12 January, 2026

Jean-Marc Coquel

Plasseraud IP is recognized by the Unified Patent Court (UPC) for its expertise in mediation and patent expertise !

Beginning in January 2026, two Industrial Property Attorneys from Plasseraud IP, representatives before the UPC, have been selected to serve on the (...)

Congratulations to our future patent attorneys !

9 December, 2025

Alexandre Collange passed the French Qualification Examination (EQF) and Marion Puimatto and Stéphane Bezac had their patent Validation of Acquired (...)

Plasseraud IP at Adopt AI – Grand Palais International Summit 2025

20 November, 2025

Jérémie Palacci

Plasseraud IP at Adopt AI – Grand Palais International Summit 2025

On 25 and 26 November 2025, Jeremie Palacci, Partner at Plasseraud IP, will participate in the Adopt AI International Summit organised by Artefact (...)

Plasseraud IP will take part in MEDICA

13 November, 2025

Atom Tong Xi Jun

The World Forum for Medicine held from November 17 to 20, 2025 in Düsseldorf, Germany. Our partner Atom TONG Xi Jun, European & Chinese Patent (...)

Allergen Alert, a deeptech company specializing in rapid food allergen detection for individuals and professionals, has raised €3.6 million in funding !

12 November, 2025

Denis Bourgarel

Allergen Alert, deeptech spécialisée dans la détection rapide des allergènes alimentaires à destination des particuliers et des professionnels, a annoncé une levée de fonds de 3,6 millions d’euros !

This investment will enable the company to finalize the technical development of its solution and accelerate the industrialization of its production (...)

Plasseraud IP is proud to sponsor the first ever trilateral seminar dedicated to young AIPPI members !

10 November, 2025

Jointly organized by the Young Members Committees of AIPPI France, Germany, and Italy, this unique event will take place on November 14, 2025, in (...)

$45 million Series A funding round for our client Genomines

6 November, 2025

Denis Bourgarel

$45 million Series A funding round for our client Genomines

Founded in 2021, Genomines is a deeptech startup that uses biotechnology to reinvent the mining industry. This funding will enable Genomines to (...)

Plasseraud IP welcomes Jérémie Palacci as Partner and strengthens its expertise in Artificial Intelligence and Quantum Computing

5 November, 2025

Jérémie Palacci

Press Release Paris, 4 November 2025 Plasseraud IP welcomes Jérémie Palacci as Partner and strengthens its expertise in Artificial Intelligence and (...)

Plasseraud IP at APAA 2025 in Kuala Lumpur

4 November, 2025

Guylène Kiesel Le Cosquer

Plasseraud IP à l’APAA 2025 à Kuala Lumpur

Our experts, Guylène Kiesel Le Cosquer, Partner and Board Member, and Ina Schreiber, Partner and Head of the Patent Department, represent Plasseraud (...)

Ipsen announces its intention to acquire ImCheck Therapeutics

4 November, 2025

Denis Bourgarel

Ipsen announces its intention to acquire ImCheck Therapeutics

On October 22, 2025, the biopharmaceutical group Ipsen announced that it had entered into a definitive agreement to acquire ImCheck Therapeutics, a (...)

On the same expertise

Plasseraud IP at the BIO-Europe Spring

11 February, 2026

Marion Puimatto

The BIO-Europe Spring conference will take place in Lisbon from March 23 to 25, 2026. Plasseraud IP will be attending the BIO-Europe by Informa (...)

Plasseraud IP at the BIO-Europe Spring

11 February, 2026

Marion Puimatto

The BIO-Europe Spring conference will take place in Lisbon from March 23 to 25, 2026. Plasseraud IP will be attending the BIO-Europe by Informa (...)

Plasseraud IP participates in the Pharma & Biotech Patent Litigation Europe conference

6 February, 2026

Plasseraud IP participe à la conférence Pharma & Biotech Patent Litigation Europe

The Pharma & Biotech Patent Litigation Europe conference will take place from January 19 to 21, 2026, in Amsterdam. Our partners Ina Schreiber, (...)

Congratulations to our future patent attorneys !

9 December, 2025

Alexandre Collange passed the French Qualification Examination (EQF) and Marion Puimatto and Stéphane Bezac had their patent Validation of Acquired (...)

Plasseraud IP at the 4th Pharma & Biotech Patent Litigation Europe Summit in Amsterdam

20 February, 2025

Plasseraud IP Amsterdam had the privilege of attending the 4th Pharma & Biotech Patent Litigation Europe Summit on January 21st and 22nd 2025, (...)

Plasseraud IP Strengthens Its European Presence with the Opening of a New Office in Amsterdam

9 January, 2025

Plasseraud IP renforce sa présence européenne avec l’ouverture d’un nouveau bureau à Amsterdam

Following its successful expansion into Munich, Shanghai, Prague, Madrid and Alicante, Plasseraud IP is pleased to announce the opening of its new (...)

On the same expertise

Business methods and patentability at the EPO: challenging the notional businessperson in decision T 1392/20

29 January, 2026

Bruno Loubet

Méthodes d’affaires et brevetabilité à l’OEB : l’homme du business fictif à l’épreuve de la décision T 1392/20

At the European Patent Office (EPO), computer-implemented inventions, especially those involving business methods, face a high bar for patentability (...)

G 1/23 (“Solar Cell”) - New Standard for Prior Art

25 July, 2025

Lilia Leghmizi

On 27 June 2023, in case T 438/19, Technical Board 3.3.03 referred key questions to the Enlarged Board of Appeal about the conditions under which a (...)

T 1580/23 : the sole mention of a telecommunication standard in the description of a European patent is not sufficient to claim an effect relative to the implementation of the standard

17 July, 2025

Bruno Loubet

T 1580/23 : la seule mention d'une norme de télécommunication dans la description d'un brevet européen ne suffit pas à revendiquer un effet relatif à la mise en œuvre de la norme

The decision T 1580/23 of the Boards of Appeal 3.5.05 of the European Patent Office (EPO) is an appeal decision concerning an opposition against the (...)

G 1/24 : Claim Interpretation at the EPO - No Legal Anchor, but a Clear(er?) Path Forward

25 June, 2025

Nadine Rocaboy

G 1/24 Claim Interpretation at the EPO: No Legal Anchor, but a Clear(er?) Path Forward

The Enlarged Board of Appeal’s recent decision in G 1/24 has provided significant clarification regarding the interpretation of claims when assessing (...)

ChatGPT is not a skilled person

28 May, 2025

Louis Lavigne

In a recent decision T 1193/23 - 3.2.06 by the Boards of Appeal of the European Patent Office (EPO), the role of artificial intelligence, (...)

“Published after but filed before”: dealing with this kind of prior art - Obtaining an EP Patent - A crash course for the US applicant #8

6 February, 2025

Nadine Rocaboy

“Published after but filed before”: dealing with this kind of prior art - Obtaining an EP Patent - A crash course for the US applicant #8

“Published after but filed before”: dealing with this kind of prior art A patent application having a filing date earlier than the filing date of (...)

Landmark Decision by the Unified Patent Court: Shedding Light on Infringement by Equivalence

3 February, 2025

Nadine Rocaboy

Landmark Decision by the Unified Patent Court: Shedding Light on Infringement by Equivalence

By the end of 2024, the Unified Patent Court (UPC) offered a wonderful gift: the first decision ruling on infringement by equivalence. The decision (...)

Opposition in France: French specificities and initial assessment of oppositions for patents in class "A61" ("Medical or veterinary science; Hygiene").

4 July, 2024

Isabelle Magnin-Feysot

Opposition in France: French specificities and initial assessment of oppositions for patents in class "A61" ("Medical or veterinary science; Hygiene").

1/ General considerations on opposition proceedings in France Opposition proceedings for French patents before the French Patent Office (INPI), are (...)

EP and US patent offices expand their uses of e-signatures

5 April, 2024

Laurence Loumes

EP and US patent offices expand their uses of e-signatures

The EPO and the USPTO have issued recent decisions to expand the use of e-signatures, including the use of commercial solutions such as DocuSign® or (...)

Patent term: how to calculate the expiration date of an EP patent? - Obtaining an EP Patent - A crash course for the US applicant #7

4 April, 2024

Nadine Rocaboy

Obtaining an EP Patent - A crash course for the US applicant #7 - Patent term: how to calculate the expiration date of an EP patent?

Patent term: how to calculate the expiration date of an EP patent? In most patent legislations, the duration of a patent is generally 20 years from (...)

*Périmètre